Markets:

Overview

News

Currencies

International

Treasuries

Arcus Biosciences, Inc. Common Stock (NY:RCUS)

20.37 +0.83 (+4.25%)

Official Closing Price Updated: 4:10 PM EST, Feb 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Arcus Biosciences, Inc. Common Stock

< Previous 1 2 3 4 5 6 Next >

Arcus (RCUS) Q4 2025 Earnings Call Transcript ↗

February 25, 2026

Arcus (RCUS) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Arcus Biosciences Inc (NYSE:RCUS) Reports Mixed Q4 2025 Results as Pipeline Strategy Pivots to Casdatifan ↗

February 25, 2026

Via Chartmill

Arcus Biosciences President Sells $2 Million as Stock Delivers 48% Annual Return ↗

January 05, 2026

Arcus Biosciences, a clinical-stage oncology innovator, reported significant insider selling as its stock capped a strong one-year return.

Via The Motley Fool

Topics Regulatory Compliance

Why Did Arcus Biosciences Stock Slump 10% Today? ↗

December 12, 2025

Arcus will stop testing a domvanalimab-based drug combination in upper gastrointestinal cancers after independent reviewers found the treatment did not improve survival.

Via Stocktwits

Analyst Expectations For Arcus Biosciences's Future ↗

October 29, 2025

Via Benzinga

Arcus Biosciences Turns Heads With 26.7-Month Survival In Gastric Cancer Study — Retail Calls It ‘Unprecedented’ ↗

October 12, 2025

Via Stocktwits

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

Earnings Scheduled For May 6, 2025 ↗

May 06, 2025

Via Benzinga

What to Expect from Arcus Biosciences's Earnings ↗

May 05, 2025

Via Benzinga

Arcus Biosciences President Sells $2 Million in Stock Under Trading Plan ↗

November 02, 2025

Arcus Biosciences President Sells $2 Million in Stock Under Trading Plan

Via The Motley Fool

Topics Regulatory Compliance

Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months ↗

October 13, 2025

Arcus Biosciences reports 26.7-month median survival and 59% response rate in Phase 2 cancer study with domvanalimab combination therapy.

Via Benzinga

How Arcus Biosciences Aims To Take On Merck In Cancer Treatment ↗

October 07, 2025

Shares climbed Tuesday as enthusiasm grows for the biotech company's experimental cancer drug.

Via Investor's Business Daily

Why Is Arcus Biosciences Stock Trading Higher On Monday? ↗

October 06, 2025

Arcus Biosciences reports casdatifan monotherapy data in renal cancer, showing a 35% response rate and median progression-free survival not yet reached.

Via Benzinga

Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday ↗

September 03, 2025

Via Benzinga

Earnings Scheduled For February 25, 2025 ↗

February 25, 2025

Via Benzinga

Expert Outlook: Arcus Biosciences Through The Eyes Of 8 Analysts ↗

November 06, 2024

Via Benzinga

Jim Cramer Recommends This Energy Stock, But Don't 'Bank It All' On Arcus ↗

August 14, 2025

On CNBC's Mad Money Lightning Round, Jim Cramer endorsed buying Uranium Energy and called Arcus Biosciences a speculative play.

Via Benzinga

Gilead Lifts Annual Outlook As Yeztugo Launch Nears ↗

August 08, 2025

Gilead raised its 2025 earnings and sales outlook after posting better-than-expected Q2 results, led by strong HIV and oncology drug sales.

Via Benzinga

Arcus (RCUS) Q2 Revenue Jumps 310% ↗

August 06, 2025

Via The Motley Fool

Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

May 06, 2025

Via Benzinga

Unveiling 5 Analyst Insights On Arcus Biosciences ↗

October 21, 2024

Via Benzinga

Where Arcus Biosciences Stands With Analysts ↗

October 21, 2024

Via Benzinga

Demystifying Arcus Biosciences: Insights From 4 Analyst Reviews ↗

October 03, 2024

Via Benzinga

Why ThredUp Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket ↗

May 06, 2025

Via Benzinga

Forecasting The Future: 5 Analyst Projections For Arcus Biosciences ↗

April 23, 2025

Via Benzinga

Arcus Biosciences Shares Are Down Today: What's Going On? ↗

February 18, 2025

Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock offering.

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

January 31, 2025

Via Benzinga

Ericsson Posts Weak Results, Joins East West Bancorp And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

January 24, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

January 24, 2025

Via Benzinga

This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

October 08, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.